Who's buying beauty
brands in 2026, and at
what multiple.

Every beauty founder I talk to at $5M to $50M in revenue has the same three numbers stuck in their head. e.l.f. paid a billion dollars for Rhode. L'Oreal paid more than two and a half billion for Aesop. Helen of Troy paid $240M for a nail-care brand doing $33M. Then they open their own P&L and land on the one question that matters: what would someone pay for this, and what would make that number climb?

The realistic range is narrower than the headlines suggest. Beauty trades at a premium to almost every other consumer category, averaging roughly 3.6x revenue across 2022 to 2025. Deals that make the news sit at the very top of that distribution, and the 4.7x and 7.2x numbers attach to brands that are high-margin, fast-growing, culturally relevant, or strategically scarce. The ordinary brand doing $20M at a respectable margin is having a very different conversation, and the gap between the two is where founder expectations get reset.

My view on this comes from sitting on the buy side. At WIN Brands Group, building consumer brands and buying others into the portfolio meant taking a founder's reported numbers apart before anyone signed, then watching what an acquirer was actually paying for once a deal cleared the sector average. Applied to a beauty P&L, that discipline is unforgiving: the margin line does most of the talking, and it's rarely what the deck says it is. A multiple is a proxy for three or four things a buyer can underwrite, and once you can name them, the market stops looking random.

The rest of this post covers who's buying beauty brands in 2026, split into the three camps that price you differently, and why strategics set the headline numbers while PE sets the floor. It walks through how revenue and EBITDA multiples get applied and which one you get, what separates a 3x exit from a 7x one, the gross-margin premium that makes beauty special, what makes a brand acquirable in the first place, and the wellness money flooding in from outside the category. If you're building a consumer brand toward a sale, this is the math that decides your outcome.

Every figure here comes from a disclosed deal or a published sector benchmark. Where a multiple is implied from deal terms, treat it as an approximation: deal terms rarely spell out enterprise value and revenue timing with much precision, so these ranges describe a market and are not a quote on your specific brand. The levers underneath the numbers are what matter, because you can move them.

The 3.6x average, and
why the headlines
mislead you.

The beauty sector averaged about 3.6x EV to revenue from 2022 through 2025, per Capstone Partners' beauty M&A coverage, which is higher than most consumer verticals. That's your anchor. The average hides a wide spread, though, and almost every deal you've read about sits well above it, because the exciting deals are the ones that get announced. The quiet, ordinary transactions that make up the middle of the distribution rarely generate a press release.

The three named deals founders quote show the pattern. e.l.f. Beauty paid roughly $1.0B for Rhode on about $212M of trailing net sales, an implied 4.7x. L'Oreal paid $2.53B for Aesop on $537M of 2022 revenue, also about 4.7x. Helen of Troy paid $240M for Olive and June on roughly $33M of sales, an implied 7.2x and the richest of the three. Each one cleared the sector average, and each one earned the premium for a reason we'll come back to: growth, margin, scarcity, or some combination.

The spread matters because if you anchor on the 4.7x Rhode number and your brand isn't a fast-growing, founder-led, billion-dollar cultural moment, you've set yourself up for a painful negotiation. A solid but unremarkable brand doing $20M at a healthy margin will get something closer to the sector average than to Rhode's multiple, and possibly below it if the growth has flattened or the margin leans on discounting. The headline brands are the exceptions.

The cleaner way to read the market is as a distribution with a fat middle and a long right tail. Most brands cluster around the 3x to 5x revenue band if they're profitable and growing at a reasonable clip. The right tail, the 5x to 8x and beyond, belongs to brands that are scarce or culturally hot. Almost nothing sells far below 3x unless it's distressed, because beauty's gross-margin profile keeps a floor under even mediocre brands. Knowing which part of that distribution you sit in shapes the whole negotiation, and your position comes from the levers in the rest of this post.

Separate the upfront number from the total deal value, because the headlines blur them. The Rhode deal was structured as $800M at closing with up to another $200M in earnout tied to three years of performance, so the "billion dollar" figure includes money Rhode only collects if it keeps hitting targets. The Touchland deal worked the same way: $700M at closing plus up to $180M contingent on hitting 2025 sales. Earnouts are how a buyer bridges the gap between what a founder believes and what the buyer will commit to today, and a large chunk of a celebrated multiple is often money you have to go earn after the close. When you read a headline number, ask how much is guaranteed and how much is a bet on the future, because those are very different outcomes for the seller.

The three camps that
buy beauty, and price
you differently.

In 2026, beauty buyers sort into three distinct camps, and which one ends up across the table from you matters more than almost anything about the brand itself. The same $25M brand can be worth 3x to one buyer and 6x to another, because they're underwriting completely different things. Knowing which camp you're built for decides whether you run the right process. I keep the camps and their 2026 deals mapped side by side in the buyer-by-buyer view of who's acquiring consumer brands, which is the quickest way to see which one is plausibly yours.

The first camp is the strategics, and they write the biggest checks: L'Oreal, e.l.f. Beauty, Helen of Troy, Coty, P&G, Unilever, and Puig. They buy for portfolio gaps, for growth they can't build organically, and for access to a younger or different consumer. These are the deals that set the headline multiples, because a strategic can underwrite synergies a financial buyer can't: distribution they already own, manufacturing scale, retail relationships, a marketing machine. When a strategic wants your brand to fill a hole in their portfolio, they'll pay above what any spreadsheet alone would justify. Their existing shelves explain a lot of that appetite: e.l.f. already owns Rhode, Unilever owns Liquid I.V., Henkel owns Olaplex, and beauty is the densest category on the ownership map for exactly that reason.

The second camp is private equity and platform aggregators, active mostly at the smaller end. They roll up sub-scale brands into a portfolio, or they back a proven founder for a second act. Their underwriting runs on EBITDA and free cash flow instead of distribution synergy, which is why the same beauty brand usually prices lower with a financial buyer than it would with a strategic writing the check. A PE firm is buying your cash generation more than your growth story, and it prices accordingly. If a financial buyer is your most likely acquirer, your EBITDA matters more than your top-line momentum.

The third camp is the legacy CPG majors, which technically sit inside the strategic group but behave differently enough to call out. P&G and Unilever want proven, profitable, scaled assets that survive being run through a giant P&L, not momentum stories that need founder magic to keep growing. They tend to buy later, bigger, and more conservatively. A brand still dependent on its founder's Instagram is exactly what a CPG major is wary of, because their machine isn't built to replicate that. The same logic surfaces in the broader consumer M&A window reopening in 2026: deal activity came back, and buyers came back choosier than before.

For a founder, the practical move is to pick your most likely buyer before you build the story you're telling. A strategic wants a growth curve and a category position worth owning. A PE exit needs clean, defensible cash flow. A CPG major needs proof that the brand runs fine without you in the room. Try to be credible to all three at once and you end up compelling to none of them, so pick one and build toward the buyer who actually wants what you're building.

Why strategics buy the
growth they can't
build themselves.

Strategics acquire for one fundamental reason: it's cheaper and faster to buy proven growth than to build it from scratch. A large beauty company has the distribution, the manufacturing, and the retail relationships, but it often can't manufacture cultural relevance or a brand that resonates with a consumer it has aged out of. So it buys one, which is the strategic playbook working as designed. The buying never really stops; it gets more selective when capital tightens.

The logic gets concrete when you look at what each strategic was solving for. e.l.f. bought Rhode for roughly $1.0B to bridge into prestige skincare and reach a younger, founder-driven consumer it didn't fully own. L'Oreal's run of deals (the Aesop purchase, a reported billion-euro-range majority stake in skincare brand Medik8, the Color Wow professional-haircare acquisition) each filled a specific portfolio gap, whether prestige, clinical skincare, or professional hair. Helen of Troy paid up for Olive and June to own a fast-growing nail-care wedge with both DTC and retail traction. Each one plugged a hole the acquirer couldn't fill organically fast enough.

This is also why the divestiture side matters as much as the acquisition side. Coty launched a strategic review of its roughly $1.2B Consumer Beauty division and signaled it may sell or spin off parts of its portfolio. When a major trims non-core brands, it frees capital and focus to buy the growth it actually wants. Estée Lauder and Puig ended merger talks to refocus on independent strategies, and Estée Lauder has been weeding underperformers. Portfolio optimization at the top creates both sellers and buyers, which is part of why the 2026 deal environment is picking up after a slow stretch.

For a founder, a brand that fills a gap a strategic needs can command a premium a pure financial model would never produce, because the strategic is buying something a spreadsheet doesn't capture. If your brand isn't a portfolio fit for anyone, the strategic premium evaporates and you're left with the financial-buyer math. The most valuable position is being the obvious answer to a specific strategic's specific problem. That's a positioning question as much as a financial one, and it needs solving years before a process starts.

I saw this pattern repeat from the buy side often enough to trust it. The brands that drew real competitive tension were clearly the missing piece in someone's portfolio, the brand a strategic would rather buy than spend three years and a lot of money trying to replicate. They weren't always the biggest or the fastest growing. When two strategics both see you as that missing piece, the multiple takes care of itself. When nobody does, you're negotiating against a discounted cash flow model, and that's a colder room.

There's a timing dimension here that founders underrate. Strategics don't buy on a steady cadence. They buy in waves, driven by where their own portfolio is weak, what their last earnings call promised investors, and how much dry powder they're sitting on after a divestiture. When a major announces it's reviewing or shedding a billion-dollar division, as Coty did with Consumer Beauty, a seller is appearing, and so is a buyer freeing up capital and attention to chase the growth it actually wants. Those signals tell you when the window for your category is open. A sale process run into a hungry strategic at the right moment clears a meaningfully higher number than the same brand sold into a quiet stretch.

The PE roll-up math,
and why it sets the
floor not the ceiling.

Private equity sets the floor on beauty multiples, and it's a different game from the strategic one. Financial buyers are active mostly at the smaller end, assembling mini-portfolios of sub-scale brands or backing founders for a second act. They model your free cash flow, stress your EBITDA, and underwrite a return, which means they're structurally less willing to pay up for growth they can't be sure will continue. The result is usually a lower revenue multiple than a strategic would offer for the same brand.

The roll-up logic is simple: a PE platform buys several small brands, centralizes the unglamorous functions (fulfillment, finance, sourcing, media buying), and tries to expand margin across the portfolio while paying entry multiples below where the combined entity might eventually trade. You can see the appetite in the deals themselves: CVC Capital acquired Korea's Serin Company, maker of the cult Dokdo Toner, for around $600M; Blackstone bought salon chain Juno Hair for roughly $590M; Bansk Group took a majority stake in BYOMA. The money is flowing into platforms with international runway and authentic positioning, and Advent's acquisition of Salt & Stone is the same body-care bet playing out in real time.

What trips founders up is that a PE buyer's lower headline multiple isn't necessarily a worse outcome. Financial buyers often bring operational discipline, a second bite of the apple through rollover equity, and a path to a larger strategic exit down the road. The right PE partner can take a founder-dependent $15M brand and build it into a $50M business that a strategic eventually pays a premium for. Structure and partner matter as much as the entry multiple, which is the same lesson that applies to how holding companies approach consumer acquisitions.

That said, the discipline cuts both ways. Because PE underwrites to cash flow, the things that flatter a revenue conversation don't help you here. Growth bought with unsustainable discounting, a margin propped up by stretching payables, a working-capital build the founder hasn't fully funded, all of it gets normalized out in the model. A financial buyer will rebuild your EBITDA from scratch and pay you on the defensible number, which is frequently several points below what you marketed. This is exactly the quality-of-earnings discipline I've written about for the EBITDA line that makes a brand sellable, and it applies with full force when PE is at the table.

The platform appetite matters because it's reshaping the smaller end of the market. After a slow stretch when higher rates made leveraged deals painful, financial sponsors are re-engaging selectively, often as the buyers of the non-core brands strategics are shedding. That opens a door for smaller brands: one too small to matter to L'Oreal can be exactly the right size for a platform building toward scale. Platforms still assembling their own portfolio also need add-on acquisitions to justify the model, which means a well-run sub-scale brand has more potential homes in 2026 than it did a couple of years ago, and more buyers competing for the good ones.

Court PE over a strategic when the brand is profitable and durable but not a category-defining cultural moment, when the founder wants to take some chips off the table while staying involved, or when the brand needs an operational partner to reach the scale a strategic would pay up for. PE is the right buyer for the steady, well-run brand that isn't going to set a headline multiple but throws off real cash. Plenty of excellent businesses fit that description, and a well-structured financial exit can be a better outcome than holding out for a strategic premium that never materializes.

One more thing the buy side taught me about financial buyers: they reward preparation more than narrative. A strategic might fall in love with a brand and talk itself into a number. A sponsor almost never does. The way you win with PE is by handing them a business that's already clean, where the contribution margin by channel is documented, the add-backs are honest, and the working capital is funded. The cleaner the data room, the less risk they have to price in, and the higher the number they can defend to their own investment committee. That kind of cleanup comes from sell-side preparation done a year earlier. With a financial buyer, the discount you avoid by being prepared is usually larger than any premium you could have talked your way into.

Revenue multiple or
EBITDA multiple: which
one you actually get.

Beauty brands get valued two different ways, and the one a buyer picks tells you exactly how they see the brand. Strategics chasing growth tend to price on revenue, roughly 3x to 5x for prestige and 5x to 8x for breakout brands. Financial buyers building portfolios anchor on EBITDA, frequently around 3x to 5x EBITDA, because they're underwriting cash flow. The healthiest brands can credibly have either conversation. The weakest get neither and end up in a distressed or earnout-heavy structure.

The revenue-multiple conversation belongs to brands where the buyer is paying for future revenue rather than current profit. A fast-growing brand with strong gross margin gets priced on its top line because the acquirer believes that line is going to keep climbing, and beauty's high gross margin means a lot of that future revenue drops toward profit. This is the conversation Rhode and Olive and June had. It's a momentum conversation, and it produces the headline numbers, but it only applies if your growth and margin justify paying ahead of the cash flow.

The EBITDA-multiple conversation belongs to steady, profitable brands where the buyer is underwriting the cash the business throws off today. Strategic deals in the sector have run rich on this basis, averaging in the mid-teens on EV to EBITDA, well above the broad consumer average, because beauty's margin profile justifies it. But for an ordinary brand being bought by a financial sponsor, the working number is closer to 3x to 5x EBITDA. The same brand can look very different depending on whether the buyer applies a beauty-sector EBITDA multiple or a generic consumer one, which is another reason the buyer's identity matters so much.

Take a brand doing $20M at, say, 10% EBITDA that dreams of 5x revenue, which would be $100M. But if its growth has cooled and a financial buyer is the realistic acquirer, the conversation is 4x to 5x EBITDA on $2M of profit, which is $8M to $10M. The gap between those two headline numbers is enormous, and it's entirely about which multiple gets applied. Founders fixate on the revenue number from the deals they read about and forget that the revenue multiple only attaches to a specific, scarce kind of brand. For everyone else, EBITDA is the conversation, and that means profit, more than sales, is what you're really building.

Be honest about which conversation your brand is built for, and then build toward the version that pays more. If you have real growth and margin, protect the growth and tell the revenue story. If you're a steady cash generator, get your EBITDA clean and defensible and tell that story. The worst outcome is a brand that tells a revenue story to a buyer who's running EBITDA math, because the mismatch shows up the moment diligence starts and the price gets reset downward.

What actually separates
a 3x exit from a
7x one.

A revenue multiple looks arbitrary from the outside, but it has a logic: it's a proxy for three things an acquirer can underwrite. The gap between a 3x exit and a 7x one comes down to how strongly your brand delivers on each of them. Get all three right and you're in the right tail of the distribution. Miss one or two and you're at the sector average or below, regardless of how good the product is. Brand quality matters, but these three levers set the price.

The first is gross margin, which is the foundation of the entire beauty premium. Public beauty runs about a 69% median gross margin, the highest of any ecommerce vertical, versus roughly 56% for broad DTC. That high gross profit is what funds the heavy marketing spend beauty brands rely on, which is exactly why acquirers pay more per dollar of revenue here than in food or apparel. A brand at 60% gross margin and one at 70% are not in the same conversation even at identical revenue, because the buyer is paying for the margin engine, not the top line. Rebuilding margin around the new import math matters here too, the way it does across contribution margin math generally.

The second is growth rate, and it moves the number more than almost anything. A brand growing 30% gets a very different multiple from one growing 8%, because the buyer is paying for where the growth curve is headed. This is where momentum brands like Rhode and Olive and June earn their premium: the acquirer is underwriting a curve, and a steep curve compounds into a lot of future profit at beauty's margins. The catch is that the growth has to be real and profitable, not bought with discounting, because a buyer can tell the difference and prices the fragile version down.

The third is operating quality and channel mix, which determines whether the multiple holds up under scrutiny. Across nine public beauty brands, operating margin ranged from about +20.5% at Inter Parfums to -6.9% at Beauty Health, a spread of more than 27 points inside one vertical. Olaplex collapsed from north of 25% operating margin to around 1.6% in roughly 18 months when its salon channel compressed. An acquirer prices that risk. A brand with durable, diversified margins gets the high end; one whose margin depends on a single channel or a discount habit gets the low end, no matter how good the recent growth looks. The same concentration discount that crushes SaaS valuations applies to beauty through channel concentration.

The gross-margin premium
that makes beauty
worth more.

Beauty commands richer multiples than apparel or food for one structural reason, the same one that draws acquirers to the category at all: gross margin. At roughly a 69% median across public beauty, versus about 56% for broad DTC, beauty generates more profit per dollar of revenue, and that profit funds the marketing machine that drives the growth a buyer is paying for. Acquirers pay for the margin and the growth, and the margin is what makes the growth fundable.

The advantage compounds. A high gross margin lets a brand spend aggressively on acquisition and still keep contribution margin positive, so it can grow faster for longer before the economics break. It leaves room to absorb a tariff shock, a freight spike, or a promotional period without falling into the red, and it pays for retention programs, sampling, and the kind of marketing that builds durable demand. A 70% gross margin funds the things that make a brand grow and stick, which is precisely what an acquirer wants to inherit.

Buyers also know that a reported margin and a durable one are different things. A 70% reported gross margin that depends on a single trading-company supplier, a fragile freight arrangement, or aggressive return assumptions is worth less than a slightly lower margin that's rock solid. This is why moving from trading-company sourcing toward direct factory relationships is often the single highest-leverage project a beauty founder can run before a sale. It's a 12 to 18 month effort, and it converts a margin that looks good on paper into one that survives diligence, which is the only kind that gets paid for.

There's a category nuance buried in the average, too. Fragrance, color cosmetics, skincare, and haircare don't all carry the same margin or the same multiple. Prestige fragrance and clinical skincare tend to anchor the high end on both margin and durability, which is part of why L'Oreal's prestige and clinical-skincare deals cleared the sector average so comfortably. Mass color cosmetics, the category Coty is reviewing for divestiture, lives at the more commoditized end. The blended 69% hides real variation, and where your sub-category sits inside it shapes both your margin ceiling and the kind of buyer who'll want you.

For an operator, gross margin is the number to defend above all others, because it justifies everything else. Every point of durable gross margin expands what you can spend to grow, what shocks you can absorb, and what an acquirer will pay per dollar of revenue. Brands that protect their margin discipline, the way the strongest brands protect their category-specific unit economics, are the ones that end up with both the healthiest business and the richest exit, and in beauty those two goals point the same way.

What actually makes a
beauty brand worth
buying.

Beyond the multiple math, a buyer is asking a more basic question: is this a brand I'd actually want to own? Five things answer it, and they're the same five whether the buyer is a strategic, a sponsor, or a CPG major. A brand that's strong on all five commands a premium and a competitive process. A brand that's weak on two of them gets a single interested buyer and a take-it-or-leave-it offer, no matter how good the product or the recent quarter looks.

One: margin you can defend. We've covered why gross margin sets the ceiling, but the word that matters is defensible. A buyer rebuilds your margin in diligence, challenges every add-back, and prices you on what survives. A reported margin that depends on stretched payables, a single supplier, or optimistic return assumptions gets normalized down. The brands that hold their multiple walk in with margin that's already been pressure-tested, which is the point of running your own quality-of-earnings review before a buyer runs theirs.

Two: retention as much as acquisition. A brand whose customers come back is a brand whose marketing spend keeps paying off, which compounds into margin and signals durability at the same time. Buyers scrutinize repeat-purchase rate and cohort curves precisely because they reveal whether the growth is a treadmill or a flywheel. A brand carrying a great new-customer number but a leaky retention profile is buying its growth over and over, and a buyer prices that fragility in. That double role is why retention punches above its weight in a valuation.

Three: a category position worth owning. This is the strategic question. Does the brand own a defensible space, a clear consumer, a hard-to-replicate cultural relevance, or is it one of a dozen interchangeable brands in a crowded shelf? The brands that command premiums are the ones a buyer would rather acquire than try to build, because building cultural relevance is slow, expensive, and uncertain. A scarce position is what pushes a brand into the 5x to 8x right tail. A me-too brand in a commodity category, however well run, stays near the sector floor.

Four: founder transferability. This is the quiet cap on a lot of multiples. A brand where the founder still writes the product roadmap, fronts the marketing, closes every key relationship, and makes the final call on everything is hard to value, because the buyer can see the asset walking out the door the moment the deal closes. It shows up as a discount even when the margin is strong, because the buyer is pricing the risk that the business can't run without you. Building a team and systems that let the brand run when the founder steps back is one of the most direct ways to protect the value you've built. It matters most at the smaller revenue bands, where the dependency is most acute. The same first operator hire that reduces founder dependency is also the one that protects your multiple.

Five: clean, diligence-ready financials. Deals die over a surprise in the data room far more often than over a low number. Clean, accrual-based books that tie out, twelve-plus months of contribution-margin data by channel, and a defensible answer for every add-back save you points on the multiple and, more importantly, keep the buyer's trust intact. A brand that can't survive diligence gets repriced for the specific problem found and for everything else the buyer now suspects. The financial visibility that makes a brand acquirable is the same financial stack a brand needs to run well in the first place.

The wellness premium,
and the buyers from
outside beauty.

Some of the richest recent deals didn't come from beauty companies at all, and that's a signal worth reading. When Church & Dwight, a household-products company best known for Arm & Hammer, paid up to $880M for Touchland, a hand-sanitizer brand doing roughly $130M in trailing sales, it paid an EBITDA multiple in the low teens for something adjacent to beauty rather than squarely inside it. The wellness and self-care halo is pulling in buyers, and dollars, from well beyond the traditional beauty acquirer pool.

For a founder, this widens the buyer universe. A brand sitting at the intersection of beauty, wellness, and self-care can attract household-products companies, consumer-health players, and food-and-beverage majors, well beyond the seven beauty strategics alone. More potential buyers means more competitive tension, and competitive tension is what actually moves a multiple. The Touchland deal is instructive because the buyer wasn't an obvious one, and an unexpected bidder like that turns a quiet process into a real auction. If that adjacency describes you, look at who is buying wellness and supplement brands in 2026 and what those brands are actually clearing on EBITDA.

The wellness premium also comes from a change in what consumers value and what acquirers are chasing. Brands that frame themselves around wellness, ritual, and self-care (as opposed to pure vanity) tend to enjoy stronger repeat behavior and a more durable emotional connection, which are exactly the durability signals a buyer pays up for. The line between a beauty brand and a wellness brand is blurring, and the brands that sit credibly on both sides of it have a structural advantage in both retention and the eventual sale.

There's a caution in the wellness gold rush, though. The premium attaches to authentic positioning and real repeat behavior, not to a wellness label slapped on an ordinary product. Buyers, especially the sophisticated ones, can tell a brand that owns a wellness ritual from one that's borrowed the language for a pitch deck. The durability has to show up in the cohort data, because a brand deck alone won't carry it, and a wellness story that the retention curves contradict is worth less than no story at all: now the buyer questions the rest of the narrative too.

The buying is global, too. Some of the most aggressive recent buying has been around platforms with international runway, particularly in K-beauty, where the combination of cult products and a clear path to Western distribution has drawn nine-figure checks from large financial sponsors. CVC's roughly $600M move on a Korean toner brand and Blackstone's roughly $590M salon-chain deal are about owning positions in fast-growing, exportable beauty and self-care categories. For a founder, geography and category adjacency can both expand who'll buy you. A brand that travels, or that bridges into an adjacent self-care category, is a brand more buyers can build a thesis around.

For an operator, the move is to build the wellness or self-care position only if it's true to the product and the customer, then prove it with retention data instead of asserting it with copy. Done honestly, it broadens your buyer pool, strengthens your repeat economics, and supports a richer multiple. Done as a veneer, it's a liability that surfaces in diligence. The brands winning the wellness premium in 2026 are the ones where the positioning and the numbers tell the same story, which is the only version a buyer will pay for.

The runway to a brand
worth a premium
multiple.

Engineering a beauty multiple in the quarter before you go to market is the most expensive mistake a founder can make, because every shortcut shows up the moment a buyer's team opens the data room. Give it 12 to 18 months instead: enough time for the margin, the retention, and the financial story to look like the ordinary state of the business rather than something dressed up for a sale. Run the phases in this order, because each one builds on the last.

Not every beauty brand needs to be engineered for a sale, and a multiple chased purely to flip the business tends to be a fragile one. This runway earns its place because everything in it makes the company better whether you ever sell or not: higher durable margin, stronger retention, diversified channels, and a founder who isn't the bottleneck. Run the 12 to 18 months, decide to keep operating anyway, and you're still left with a healthier, more valuable, cash-generating brand. Sale-readiness ends up as a byproduct of building well.

The other thing this runway buys you is optionality. A brand that's margin-strong, durable, and clean can credibly run a process with strategics, sponsors, and CPG majors all at the table, which is exactly the competitive tension that moves a multiple. A brand that's only attractive to one type of buyer has no leverage. The work above lifts your number and widens the room, and a wider room is what turns a fair price into a premium one.

The beauty multiple is a proxy for a handful of things a buyer can underwrite: gross margin, growth, durability, category position, and a business the founder isn't required to run. Headline deals like the 4.7x Rhode and the 7.2x Olive and June attach to brands that deliver strongly on all of them, which is why they sit in the right tail. The sector average of roughly 3.6x is where the broad middle lives, and below it is where the discount-dependent, founder-bound, single-channel brands end up no matter how good the product is. Your job is to know which part of that distribution you're building toward, and to build on purpose for the buyer most likely to want you.

If you're building a beauty or consumer brand toward a sale and want to know what an acquirer will actually pay, and what's quietly capping your number, that's the same buy-side diligence I ran at WIN Brands Group, pointed at your brand before a buyer points it there first. This is exactly what the DTC growth consultant engagement is built for, and the profitability teardown is a good place to see how far the real numbers can drift from the deck.

Questions from founders
building toward a
beauty exit.